These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 38655259)

  • 1. Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.
    Mehraj V; Chen J; Routy JP
    Front Immunol; 2024; 15():1339338. PubMed ID: 38655259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
    Gebhardt A; Fichtenbaum CJ
    Expert Opin Pharmacother; 2019 Oct; 20(14):1719-1729. PubMed ID: 31232617
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of statins in the setting of HIV infection.
    Eckard AR; McComsey GA
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.
    Riestenberg RA; Furman A; Cowen A; Pawlowksi A; Schneider D; Lewis AA; Kelly S; Taiwo B; Achenbach C; Palella F; Stone NJ; Lloyd-Jones DM; Feinstein MJ
    Am Heart J; 2019 Mar; 209():79-87. PubMed ID: 30685678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
    Grinspoon SK; Fitch KV; Overton ET; Fichtenbaum CJ; Zanni MV; Aberg JA; Malvestutto C; Lu MT; Currier JS; Sponseller CA; Waclawiw M; Alston-Smith B; Cooper-Arnold K; Klingman KL; Desvigne-Nickens P; Hoffmann U; Ribaudo HJ; Douglas PS;
    Am Heart J; 2019 Jun; 212():23-35. PubMed ID: 30928825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.
    Zanetti HR; Roever L; Gonçalves A; Resende ES
    Curr Atheroscler Rep; 2018 Feb; 20(2):9. PubMed ID: 29423787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.
    Fitch KV; Fulda ES; Grinspoon SK
    Curr Opin HIV AIDS; 2022 Sep; 17(5):293-300. PubMed ID: 35938463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
    Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
    Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Disease, Statins, and HIV.
    Eckard AR; Meissner EG; Singh I; McComsey GA
    J Infect Dis; 2016 Oct; 214 Suppl 2(Suppl 2):S83-92. PubMed ID: 27625435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Lowering Therapy: An Era Beyond Statins.
    Abdul-Rahman T; Bukhari SMA; Herrera EC; Awuah WA; Lawrence J; de Andrade H; Patel N; Shah R; Shaikh R; Capriles CAA; Ulusan S; Ahmad S; Corriero AC; Mares AC; Goel A; Hajra A; Bandyopadhyay D; Gupta R
    Curr Probl Cardiol; 2022 Dec; 47(12):101342. PubMed ID: 35918009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.
    Looby SE; Kantor A; Burdo TH; Currier JS; Fichtenbaum CJ; Overton ET; Aberg JA; Malvestutto CD; Bloomfield GS; Erlandson KM; Cespedes M; Kallas EG; Masiá M; Thornton AC; Smith MD; Flynn JM; Kileel EM; Fulda E; Fitch KV; Lu MT; Douglas PS; Grinspoon SK; Ribaudo HJ; Zanni MV
    Clin Infect Dis; 2022 Oct; 75(8):1324-1333. PubMed ID: 35235653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.